Edge Therapeutics, Inc. (EDGE) At $16.99 Forms Bottom; Magellan Midstream Partners, L.P. (MMP) Had 12 Bullish Analysts

Edge Therapeutics, Inc. (EDGE) formed multiple bottom with $16.31 target or 4.00% below today’s $16.99 share price. Edge Therapeutics, Inc. (EDGE) has $524.47M valuation. The stock increased 5.20% or $0.84 during the last trading session, reaching $16.99. About 97,621 shares traded. Edge Therapeutics, Inc. (NASDAQ:EDGE) has risen 23.72% since March 27, 2017 and is uptrending. It has outperformed by 7.02% the S&P500.

Among 23 analysts covering Magellan Midstream Partners L.P. (NYSE:MMP), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Magellan Midstream Partners L.P. had 62 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Credit Suisse on Monday, August 10. The firm has “Buy” rating given on Wednesday, July 13 by Ladenburg Thalmann. RBC Capital Markets maintained the stock with “Hold” rating in Sunday, October 1 report. Credit Suisse downgraded Magellan Midstream Partners, L.P. (NYSE:MMP) rating on Thursday, March 17. Credit Suisse has “Underperform” rating and $70 target. The company was downgraded on Monday, July 10 by Mizuho. UBS upgraded it to “Buy” rating and $8200 target in Tuesday, July 18 report. The firm has “Outperform” rating by RBC Capital Markets given on Friday, April 29. Stifel Nicolaus maintained Magellan Midstream Partners, L.P. (NYSE:MMP) on Thursday, September 7 with “Hold” rating. JP Morgan maintained the shares of MMP in report on Monday, May 16 with “Neutral” rating. The firm has “Buy” rating by DA Davidson given on Monday, November 16. See Magellan Midstream Partners, L.P. (NYSE:MMP) latest ratings:

16/03/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $73 New Target: $69 Maintain
13/03/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $78 New Target: $75 Maintain
02/03/2018 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $80 New Target: $81 Maintain
02/02/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $78 New Target: $77 Maintain
02/02/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $69.0 Maintain
02/02/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $78 New Target: $76 Maintain
01/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $79.0 Maintain
16/01/2018 Broker: RBC Capital Markets Rating: Hold New Target: $81.0 Maintain
05/01/2018 Broker: Credit Suisse Rating: Underperform New Target: $61 Initiates Coverage On
04/01/2018 Broker: U.S. Capital Advisors Old Rating: Overweight New Rating: Buy Upgrade

Among 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Edge Therapeutics has $34 highest and $18 lowest target. $27.25’s average target is 60.39% above currents $16.99 stock price. Edge Therapeutics had 5 analyst reports since October 26, 2015 according to SRatingsIntel. The rating was initiated by Leerink Swann with “Outperform” on Monday, October 26. The rating was initiated by Credit Suisse with “Outperform” on Monday, October 26. The company was initiated on Monday, October 26 by JMP Securities. The firm has “Buy” rating by Guggenheim given on Monday, October 26. The stock has “Outperform” rating by Credit Suisse on Monday, May 9.

Investors sentiment decreased to 0.76 in Q3 2017. Its down 0.14, from 0.9 in 2017Q2. It turned negative, as 42 investors sold Magellan Midstream Partners, L.P. shares while 161 reduced holdings. 40 funds opened positions while 142 raised stakes. 134.51 million shares or 2.12% more from 131.72 million shares in 2017Q2 were reported. Texan Capital Management has invested 1.1% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP). 6,300 were reported by Middleton Co Ma. Goldman Sachs Gru Inc invested 0.17% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP). Raymond James & Assocs owns 0.12% invested in Magellan Midstream Partners, L.P. (NYSE:MMP) for 850,439 shares. Perigon Wealth Mgmt Limited Liability Co has invested 0.02% in Magellan Midstream Partners, L.P. (NYSE:MMP). Amg Funds Ltd Liability Corp holds 0.82% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP) for 20,952 shares. Huntington Steele Limited holds 2.3% or 109,626 shares in its portfolio. Howe Rusling holds 1.07% or 81,321 shares. California Employees Retirement Systems reported 0.05% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP). Cutter Brokerage holds 0.32% in Magellan Midstream Partners, L.P. (NYSE:MMP) or 11,251 shares. Cantab Capital Prns Limited Liability Partnership holds 320 shares or 0% of its portfolio. Associated Banc has 0.05% invested in Magellan Midstream Partners, L.P. (NYSE:MMP) for 12,252 shares. Moreover, Cincinnati Ins has 0.22% invested in Magellan Midstream Partners, L.P. (NYSE:MMP). Exane Derivatives holds 16 shares. Summit Equities Incorporated reported 13,914 shares or 0.18% of all its holdings.

Magellan Midstream Partners, L.P. engages in the transportation, storage, and distribution of refined petroleum products and crude oil in the United States. The company has market cap of $13.43 billion. The firm operates through Refined Products, Crude Oil, and Marine Storage divisions. It has a 15.45 P/E ratio. It operates refined products pipeline that transports gasoline, distillates, aviation fuels, and liquefied petroleum gases for independent and integrated oil companies, wholesalers, retailers, traders, railroads, airlines, and regional farm cooperatives; and provides services, including terminalling, ethanol and biodiesel unloading and loading, additive injection, custom blending, laboratory testing, and data services.